GSK 2849330

Drug Profile

GSK 2849330

Alternative Names: Anti-HER3-monoclonal-antibody; GSK-2849330

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 18 Sep 2017 GlaxoSmithKline completes a phase I trial for Solid tumours (Late-stage disease) in Australia, USA and Netherlands (IV) (NCT01966445)
  • 01 Jun 2016 GlaxoSmithKline completes a phase I PET study for Solid tumours (Late-stage disease) in the Netherlands (NCT02345174)
  • 06 May 2016 Pharmacodynamics data from a preclinical study presented at the at 107th Annual Meeting of the American Association for Cancer Research(AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top